PATIENT MONITORING FOR WM

Patient Monitoring1

 

  • Monitor for bleeding and manage
  • Monitor patients for fever and infections, evaluate promptly, and treat
  • Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function
  • Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment. See Dosage and Administration
  • Monitor blood pressure and initiate or adjust anti-hypertensive medication as appropriate and follow dosage modification guidelines for Grade 3 or higher hypertension
  • Check complete blood counts monthly for cytopenias
  • Other malignancies have occurred in patients, including skin cancers and other carcinomas
  • Assess baseline risk for tumor lysis syndrome. Take precautions, monitor, and treat
  • Advise women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy
  • Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose
  • Advise males with female partners of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose
  • Advise women not to breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose

WM=Waldenström's Macroglobulinemia.

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.